• FDA clearance quickly follows Photonova Spectra's debut at the Radiological Society of North America (RSNA) 2025 Annual Meeting, marking rapid momentum for GE HealthCare's innovative photon-counting CT technology
  • Photonova Spectra introduces the next generation of spectral photon-counting CT technology with 8‑bin energy resolution, powered by GE HealthCare's proprietary Deep Silicon detector technology and a one‑scan universal workflow designed to boost efficiency and reduce complexity across a wide range of CT exams
  • Photonova Spectra is a result of the company's $5.1 billion innovation investment, leading to a wave of transformational products across the portfolio which combined are expected to drive 1-2% revenue growth

GE HealthCare (NASDAQ:GEHC) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Photonova™ Spectra,i an innovative photon‑counting computed tomography (PCCT) solution powered by the company's novel Deep Silicon detector technology and offered as a flexible platform with multiple configurations to meet diverse clinical needs. With wide coverage and the combination of ultra-high definition (UHD) spatial and spectral imaging, Photonova Spectra helps enable fast acquisition speeds and the precise visualization of subtle tissue variations, small lesions and vascular structures.